# A Study to Learn About How Safe Nitroglycerin is and How it Affects the Body When Taken Along With Nurandociguat in People With Coronary Artery Disease

> **NCT07431294** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Bayer** · enrollment: 36 (estimated)

## Conditions studied

- Stable Coronary Artery Disease

## Interventions

- **DRUG:** Nitroglycerin spray
- **DRUG:** Nurandociguat
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07431294
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-13
- **Primary completion:** 2026-12-04
- **Final completion:** 2026-12-04
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2026-05-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07431294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07431294, "A Study to Learn About How Safe Nitroglycerin is and How it Affects the Body When Taken Along With Nurandociguat in People With Coronary Artery Disease". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT07431294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*